Aspirin for primary prevention of cardiovascular disease in women: Does sex matter?

Medical Journal of Australia

Volumn 184, Issue 6, 2006, Pages 260-261

  Hung, Joseph ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA CAROTENE; PLACEBO;

BLOOD TRANSFUSION; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH PROGRAM; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MORTALITY; PRIMARY PREVENTION; RISK ASSESSMENT; RISK REDUCTION; SCORING SYSTEM; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

EID: 33645467761     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2006.tb00231.x     Document Type: Editorial

References (12)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
2. Hung J. Aspirin for cardiovascular disease prevention. Med J Aust 2003; 179: 147-152.
3. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002; 136: 161-172.
4. National Heart Foundation Australia. Aspirin for cardiovascular disease prevention. Available at: http://www.heartfoundation.com.au/index.cfm?page=39 (accessed Feb 2006).
5. Ridker PM, Cook NR, Lee I-M, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
6. Berger JS, Roncaglioni MC, Avanzini F, et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-anlysis of randomized controlled trials. JAMA 2006; 295: 306-313.
7. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321: 129-135.
8. Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged 70. BMJ 2005; 330: 1306.
9. Montgomery PR, Berger LD, Miteno PA, Sitar DS. Salicylate metabolism: effects of age and sex in adults. Clin Pharmacol Ther 1986; 39: 571-576.
10. Levin RJ, Harpel PC, Well D, et al. Aspirin inhibits vascular plasminogen activator in vivo: studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 1984; 74: 571-580.
11. Iemolo F, Martiniuk A, Steinman DA, Spence JD. Sex differences in carotid plaque and stenosis. Stroke 2004; 35: 477-481.
12. National Heart Foundation. Aspirin for cardiovascular disease prevention. Position statement 2003 (addendum 2005). Avalable at: http://www.heartfoundation.com.au/index.cfm?page+39. (accessed Mar 2006).